← Eichor
Study identifier: NCT06036381 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis

Condition: Glioma  ·  Sponsor: Tata Memorial Centre

PhaseN/A
Planned participants1000
Who can joinAll sexes, 1 Year to no upper limit
Healthy volunteersNo

About this study

Glioma are type of primary brain tumors arising within the substance of brain. Different type of gliomas are seen which are classified depending upon pathological examination and advanced molecular techniques, which help to determine the aggressiveness of the tumor and outcomes. Artificial intelligence uses advanced analytical process aided by computer which can be undertaken on the medical images. We plan to use artificial intelligence techniques to identify the abnormal areas within the brain representing tumor from the radiological images. Also, similar approach will be undertaken to classify gliomas with good or bad prognosis, to differentiate glioma from other type of brain tumors, and to detect response after treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Dr. ARCHYA DASGUPTA, MD  ·  022-24177000  ·  archya1010@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tata Memorial HospitalMumbai, Maharashtra, IndiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06036381